The ECOG-ACRIN Cancer Research Group (EA) is dedicated to decreasing the burden of cancer. EA is a vibrant member of the National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP), focused on practice-changing clinical and translational research across the cancer care continuum from prevention and early detection, through the management of advanced disease and its impact. As an NCORP Research Base, EA has engaged community providers and researchers to develop a robust research portfolio that spans Cancer Prevention, Cancer Control, and Cancer Care Delivery, aligned with the overall scientific themes of precision oncology, immuno-oncology, reducing overdiagnosis and overtreatment, and leveraging novel biomarker platforms. Cancer control trials examine and intervene on challenges associated with cancer and treatment-related symptoms and concerns. EA's portfolio of therapeutic trials yield opportunities to apply patient-reported outcomes measurement science to quantify health-related quality of life, symptoms, and domains most relevant to patients in the context of evolving treatment paradigms. Behavioral and biomarker-driven symptom interventions aim to improve quality of life and cancer survivorship. Cardiotoxicity research aims to mitigate risk through quantifying cardiotoxicity associated with treatment, identifying groups at risk, and advancing interventions to reduce risk. Prevention trials embrace the NCI's broad definition of prevention to include primary prevention, cancer screening, and secondary prevention and aim to identify high risk groups for precision prevention strategies. Cancer Care Delivery Research (CCDR) examines the complex interactions between patient, provider, and system factors that influence care, and adapts and evaluates interventions in heterogenous community oncology practices. Health equity research permeates EA science through embedding disparities-related research questions that span EA activities, adopting a broad view of underserved populations including adolescents and young adults, the elderly, racial and ethnic minorities, sexual and gender minorities and rural residents. Key collaborations with community-based oncology programs will ensure access to EA NCTN and NCORP trials in communities where patients receive their care. EA provides access to existing NCI-funded resources and a network of >10000 physicians, scientists, nurses, research associates (RAs), statisticians, biomedical information technologists, and patient advocates across approximately 600 institutions and organizations. EA has provided scientific leadership in the NCORP community through advancing rigorous, practice-changing clinical trials and translational research in cancer control, prevention and care delivery and is well poised to continue to support the NCI's mission to engage community-based diverse populations in cancer research.

Public Health Relevance

The primary goals of the ECOG-ACRIN NCORP Research Base are: 1) to advance our understanding of approaches to prevent cancer and cancer-related physical and psychological symptoms, and 2) to develop and evaluate strategies to translate advances in high quality cancer care delivery into community oncology settings, with the aim of reducing the burden of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Lee, Cecilia H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ecog-Acrin Medical Research Foundation
United States
Zip Code
Charkhchi, Paniz; Fazeli Dehkordy, Soudabeh; Carlos, Ruth C (2018) Housing and Food Insecurity, Care Access, and Health Status Among the Chronically Ill: An Analysis of the Behavioral Risk Factor Surveillance System. J Gen Intern Med 33:644-650
Gee, Michael S; Atri, Mostafa; Bandos, Andriy I et al. (2018) Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology 287:176-184
Gareen, Ilana F; Black, William C; Tosteson, Tor D et al. (2018) Medical Care Costs Were Similar Across the Low-dose Computed Tomography and Chest X-Ray Arms of the National Lung Screening Trial Despite Different Rates of Significant Incidental Findings. Med Care 56:403-409
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Boxerman, Jerrold L; Zhang, Zheng; Safriel, Yair et al. (2018) Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Neuro Oncol 20:1400-1410
Zhao, Fengmin; Cella, David; Manola, Judith et al. (2018) Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Support Care Cancer 26:1889-1895
Cathcart-Rake, Elizabeth J; Zemla, Tyler; Jatoi, Aminah et al. (2018) Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups. Cancer :
Estabrook, Ryne; Cella, David; Zhao, Fengmin et al. (2018) Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805. Qual Life Res 27:1589-1597
Henderson, Tara O; Parsons, Susan K; Wroblewski, Kristen E et al. (2018) Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer 124:136-144
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 100 publications